Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
In vivo Car-T gains traction
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
The company buys Belgium’s EsoBiotec for $425m.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
